Evaluation of probe drugs and pharmacokinetic metrics for CYP2D6 phenotyping

By Frank D.   Jaehde U.   Fuhr U.  

European Journal of Clinical Pharmacology, Vol. 63, Iss. 4, 2007-04 ,pp. : 321-333

Springer Publishing Company

Access to resources Recommend Favorite

Effects of Polymorphism of the β₁ Adrenoreceptor and CYP2D6 on the Therapeutic Effects of Metoprolol

By Yuan H   Huang Z   Yang G   Lv H   Sang H   Yao Y  

The Journal of International Medical Research, Vol. 36, Iss. 6, 2008-11 ,pp. : 1354-1362

Field House Publishing

Access to resources Recommend Favorite

The effect of mirabegron, a potent and selective β₃-adrenoceptor agonist, on the pharmacokinetics of CYP2D6 substrates desipramine and metoprolol

By Krauwinkel Walter   Dickinson James   Schaddelee Marloes   Meijer John   Tretter Reiner   Wetering Jeroen   Strabach Gregory   Gelderen Marcel  

European Journal of Drug Metabolism and Pharmacokinetics, Vol. 39, Iss. 1, 2014-03 ,pp. : 43-52

Springer Publishing Company

Access to resources Recommend Favorite

Impact of CYP2D6 Genetic Variation on the Response of the Cardiovascular Patient to Carvedilol and Metoprolol

By  

Current Drug Metabolism, Vol. 17, Iss. 1, 2016-01 ,pp. : 30-36

Bentham Science Publishers

Access to resources Recommend Favorite

The pharmacokinetics of ketobemidone are not affected by CYP2D6 or CYP2C19 phenotype

By Al-Shurbaji Ayman   Säwe Juliette  

European Journal of Clinical Pharmacology, Vol. 57, Iss. 12, 2002-02 ,pp. : 877-881

Springer Publishing Company

Access to resources Recommend Favorite